VIRIDIAN THERAPEUTICS INC
VRDNNASDAQTrading Snapshot
- Day Range
- $23.68 – $24.41
- 52-Week Range
- $13.18 – $34.29
- Volume (shares)
- 104,901
- Avg Volume (shares)
- —
- Shares Outstanding
- 113.3M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 38.1x
- EPS (TTM)
- $-3.90
- Dividend Yield
- —
VIRIDIAN THERAPEUTICS INC
VRDNFinancial history unavailable.
StockOtter · stockotter.spaceAbout VIRIDIAN THERAPEUTICS INC
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
News unavailable.